To further clarify whether NET-DNA-CCDC25 axis also leads to chemoresistance in HER2-enriched breast cancer, we applied an anti-CCDC25 neutralizing mAb combined with chemotherapy in the spontaneous MMTV-PyMT FVB/NJ mouse model, which is a widely used genetically engineered mouse model to investigate EMT-related mechanisms (56). This evidence concerns the gene ERBB2 and breast cancer.